Beta Drugs Ltd. · NSE:BETA
Beta Drugs — Investor Presentation (November 2024)
30 slides from Beta Drugs's investor presentation, Nov 6, 2024
Slide 1: Investor Presentation H1'25
Investor Presentation H1’25
Slide 2: H1'25: Key Highlights
Healthy growth in Domestic own brand, API & International business Strong financial growth H1’25: Key Highlights Increased contribution of new launch products ZAZIBONA audit successfully completed
Slide 3: Healthy Growth in H1'25 (Y-O-Y)
Healthy Growth in H1’25(Y-O-Y) DOMESTIC OWN International API Business BRAND business 30 % growth* 141 % growth 20 % growth * Including cosmeceutical sales
Slide 4: H1'25: Improvement in Financial Performance
H1’25: Improvement in Financial Performance PERFORMANCE Growth FY’22 FY’23 FY’24 H1’24 H1’25 over (Rs Cr) (Rs Cr) (Rs Cr) (Rs Cr) (Rs Cr) H1’24 Total revenue 183.84 227.11 295.71 141.27 180.3 28% EBITDA 43.45 53.88 61.36 33.39 40.31 21% PAT 24.83 30.72 36.4 19.87 24.44 30%
Slide 5: Financial Performance
Financial Performance ------------------------------------------------------------------------------ ROCE Debt to equity ratio 35.1% 0.21 0.16 33.2% 0.13* 32.1% 0.10 30.4% FY'22 FY'23 FY'24 H1'25 FY'22 FY'23 FY'24 H1'25 * New ₹5 crore term loan secured in FY'25 for development of R&D and new corpora
Slide 6: Domestic Own Brand Business
Domestic Own Brand Business Finished formulation sales: Oncology • More than 1500 prescribers 82.2 Values in Cr 68.4 • 10 brands are in top 5 55.2 51.2 • Deeper penetration in private, corporate & government hospitals • Added 200+ new prescribers in H1’25 FY'22 FY'23 FY'24 H1'25 • Strengthen support
Slide 7: International Business
International Business Growth drivers Geo expansion Initiated commercialization in 3 major Key regulatory Achievement in H1’25 countries: Algeria, Peru & Philippines 193 new dossiers shared to respective Plan in H2: Colombia, Mexico, Azerbaijan, countries South Africa, Malaysia, Vietnam, Thailand, 2
Slide 8: About Company
AX BETA RQ A DRUGS LTD. About Company
Slide 9: Fastest Growing Indian Oncology Company
Fastest Growing Indian Oncology Company Market Reach Manufacturing and R&D Capabilities Global footprint- Present in 46+ countries Domestic market - Prescence in 85% 3 Manufacturing facilities: 2 formulation & corporate & govt hospitals 1 API manufacturing facility Employees Product pipeline 1000+ e
Slide 10: Our Approach
Our Approach With patients at the center, our approach is driven by three pillars of Market Leadership, Productivity and Innovation LEADERSHIP IN NICHE SEGMENT • Focus on ‘products that matter’ • Economy of scale, complex and clinically differentiated products Patient centricity INCREASE PRODUCTIVIT
Slide 11: Offering Quality Affordable Healthcare Products
Offering Quality Affordable Healthcare Products Our coverage in different segments of Oncology - Present in Oncology & Cosmeceutical therapeutic areas - 125+ products in Oncology - Products available in more 85% of corporate & Govt hospitals
Slide 12: Most Active in NDDS Formulations with Limited Competition
Most Active in NDDS Formulations with Limited Competition With the help of our Research and Development 8
Slide 13: Becoming a high performing healthcare company by leveraging our key strengths
Becoming a high performing healthcare company by leveraging our key strengths Focus on Own brand sales in Domestic & international market Key Strengths Manufacturing- Backward integration R&D is a major strength
Slide 14: Focus on Research & Development
Focus on Research & Development R&D focused on NDDS/novel formulations & non infringing synthesis of off-patent products
Slide 15: New product development are pivotal to our growth
Focus on Research & Development New product development are pivotal to our growth Year wise number of new brand launches 7 7 7 7 3 NDDS 5 3 5 6 7 4 New Products FY'20 FY'21 FY'22 FY'23 FY'24 FY'25 3
Slide 16: New product development are pivotal to our growth
Focus on Research & Development New product development are pivotal to our growth 3 new brands launched in H1’25: Glushield, Set to launch new NDDS formulations in H2’25 Adloid & Karezus Working on FFTLs to be launched in FY’24
Slide 17: Manufacturing
Manufacturing Formulation and API plant 3 Manufacturing facilities High level of backward integration from conception to commercialization 70% of API requirements are manufactured in-house 120+ SKUs Manufacturing wide range of finished formulation products Strong R&D Various forms of oral solids, li
Slide 18: Backward integration – key to higher margins
Backward integration – key to higher margins Wide portfolio of API 70% API facility with a world-class related to Oncology drugs of API for formulations microbial lab with the latest manufactured in-house equipment API business provides competitive advantage API business Values in Cr 20.7 Strategic
Slide 19: Focus on Own Brand Sales in Domestic & International Market
Focus on Own Brand Sales in Domestic & International Market
Slide 20: Leveraging our Strength for the Growth in Domestic Market
Leveraging our Strength for the Growth in Domestic Market Increasing our presence in tier 2 & tier 3 cities Our products are cost effective due NDDS formulations are giving backward integration. It is helping competitive edge to grow in us to get entry in more number of domestic market Govt & corpor
Slide 21: Making Inroads in Cosmeceutical Market
Making Inroads in Cosmeceutical Market - PAN India presence - Increased reach to 6000 customers Reached to the average sales of 1 Cr sales /month Growth: 105 % vis a vis H1’24 Presence A big leap… Grow Acquire Expand Increased prescriber base from 700 to 1100 • Expanded portfolio • Agreement with th
Slide 22: International Business
International Business Present in more than 46 countries 250+ registrations
Slide 23: Leveraging our Strength for the Growth in International Market
Leveraging our Strength for the Growth in International Market Global accreditations to expand the international business across the globe 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Eurasia ZAZIBONA DHA Nepal Tanzania INVIMA EUGMP (Triggered) Uganda Nigeria Cambodia Ethiopia WHO GMP ANVISA Ke
Slide 24: International Business: Focus on product registrations
International Business Focus on product registrations International Market Robust pipeline ahead Existing registrations Pipeline Middle East & Middle East Africa & Africa 47 LATAM South East Asia LATAM South East Asia 203 170 97 75 209 CIS: 12 CIS: 50 231 registrations as on date 600+ registrations
Slide 25: Our CDMO Partners
Our CDMO Partners ✓ Partnership with 50+ companies Trusted ✓ 20+ top pharma companies are associated with us since last 5 years Partners ✓ One new dedicated injectable block added at Adley formulations plant with 2 more lyophilizer (Production started) We value our ✓ Capacity of lyophilized products
Slide 26: We are a Preferred Partner for Many Top Indian Pharma Companies
We are a Preferred Partner for Many Top Indian Pharma Companies Because of… Mass Production Capability
Slide 27: Clear roadmap to become one of the largest oncology companies in India
Clear roadmap to become one of the largest oncology companies in India Launch of new products 1 Beta Drugs Ltd is amongst the first companies to launch of the new products going off patented Launch of NDDS 2 Launch NDDS for key molecules which have not been launched by any competitor Expansion into
Slide 28: Consolidate Balance Sheet
Consolidate Balance Sheet FY’22 FY’23 FY’24 H1’24 H1’25 (Rs Cr) (Rs Cr) (Rs Cr) (Rs Cr) (Rs Cr) Share capital 9.61 9.61 9.61 9.61 9.61 Reserves 82.73 113.27 147.5 132.36 171.25 Borrowing (Long 16.58 16.04 15.42 19.06 term & short term) 11.00 Other liabilities 48.93 59.5 85.98 79.87 94.59 Total liabi
Slide 29: Disclaimer
Disclaimer • This corporate presentation has been prepared by Beta Drugs Limited (the “Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. • This presentation should not be construed as legal, tax,
Slide 30: Thank You
THANK YOU Head office: SCO 184, Sector 5 Panchkula 134114 Haryana (India) Website: www.betadrugslimited.com Email: info@betadrugslimited.com